文献速递妇科生殖医学

全氟烷基和多氟烷基物质(PFAS)及其对卵巢的影响

Perfluoroalkyl and polyfluoroalkyl substances (PFAS) and their effects on the ovary.
PubMed 文献 · Hum Reprod Update · 2020-01-01

本文综述了关于PFAS暴露与卵巢功能关联的人群和毒理学研究。临床证据显示PFAS存在于卵泡液中并能穿过血-卵泡屏障,多项流行病学研究(多为横断面设计)发现较高PFAS暴露与月经初潮较晚、月经周期不规律、周期较长、绝经年龄较早及雌激素和雄激素水平降低相关,实验模型证实PFAS对卵泡生成和类固醇生成有不良影响,但证据尚不足以推断因果关系,需更多研究。

要点

  • PFAS存在于卵泡液并可穿过血-卵泡屏障。
  • 较高PFAS暴露与月经初潮较晚、周期不规律、绝经较早及雌激素和雄激素降低相关。
  • 证据尚不足以推断PFAS暴露与卵巢疾病间的因果关系,需更多研究。

核心结论

  • 已发表文献支持PFAS暴露与不良生殖结局相关,但证据仍不足以推断PFAS暴露与卵巢疾病间的因果关系,因此需更多研究。

研究设计与样本

  • 本综述通过检索PubMed进行,检索词包括广泛的PFAS及健康相关术语,从一般关键词(如卵巢、生殖、卵泡、卵母细胞)到特定关键词(包括月经初潮、月经周期、绝经、原发性卵巢功能不全/卵巢早衰、类固醇激素),基于作者对主题和关键术语的了解。

主要发现

  • 临床证据表明卵泡液中存在PFAS,且PFAS能够穿过血-卵泡屏障。
  • 尽管一些研究未发现PFAS暴露与卵巢功能紊乱相关的证据,但众多流行病学研究(多采用横断面研究设计)发现较高PFAS暴露与月经初潮较晚、月经周期不规律、周期长度较长、绝经年龄较早以及雌激素和雄激素水平降低相关。
  • 实验模型已证实PFAS对卵巢卵泡生成和类固醇生成有不良影响。
  • 基于实验室研究结果,PFAS可能通过激活过氧化物酶体增殖物激活受体、破坏卵母细胞与颗粒细胞间的间隙连接细胞间通讯、诱导甲状腺激素缺乏、拮抗参与卵巢类固醇生成的卵巢酶活性或抑制下丘脑kisspeptin信号,从而减少卵巢储备并降低内源性激素合成。

关键数值与推荐

  • 原文未报告具体数值标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 证据仍不足以推断PFAS暴露与卵巢疾病间的因果关系。
  • 需更多研究。
  • 需要开展更多使用与一般人群暴露水平相当的PFAS剂量及化合物混合物的实验研究。
  • 也需要在人群中开展前瞻性研究以确保PFAS暴露与健康终点的时间顺序并尽量减少反向因果的可能性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Perfluoroalkyl and polyfluoroalkyl substances (PFAS) are found widespread in drinking water, foods, food packaging materials and other consumer products. Several PFAS have been identified as endocrine-disrupting chemicals based on their ability to interfere with normal reproductive function and hormonal signalling. Experimental models and epidemiologic studies suggest that PFAS exposures target the ovary and represent major risks for women's health. OBJECTIVE AND RATIONALE: This review summarises human population and toxicological studies on the association between PFAS exposure and ovarian function. SEARCH METHODS: A comprehensive review was performed by searching PubMed. Search terms included an extensive list of PFAS and health terms ranging from general keywords (e.g. ovarian, reproductive, follicle, oocyte) to specific keywords (including menarche, menstrual cycle, menopause, primary ovarian insufficiency/premature ovarian failure, steroid hormones), based on the authors' knowledge of the topic and key terms. OUTCOMES: Clinical evidence demonstrates the presence of PFAS in follicular fluid and their ability to pass through the blood-follicle barrier. Although some studies found no evidence associating PFAS exposure with disruption in ovarian function, numerous epidemiologic studies, mostly with cross-sectional study designs, have identified associations of higher PFAS exposure with later menarche, irregular menstrual cycles, longer cycle length, earlier age of menopause and reduced levels of oestrogens and androgens. Adverse effects of PFAS on ovarian folliculogenesis and steroidogenesis have been confirmed in experimental models. Based on laboratory research findings, PFAS could diminish ovarian reserve and reduce endogenous hormone synthesis through activating peroxisome proliferator-activated receptors, disrupting gap junction intercellular communication between oocyte and granulosa cells, inducing thyroid hormone deficiency, antagonising ovarian enzyme activities involved in ovarian steroidogenesis or inhibiting kisspeptin signalling in the hypothalamus. WIDER IMPLICATIONS: The published literature supports associations between PFAS exposure and adverse reproductive outcomes; however, the evidence remains insufficient to infer a causal relationship between PFAS exposure and ovarian disorders. Thus, more research is warranted. PFAS are of significant concern because these chemicals are ubiquitous and persistent in the environment and in humans. Moreover, susceptible groups, such as foetuses and pregnant women, may be exposed to harmful combinations of chemicals that include PFAS. However, the role environmental exposures play in reproductive disorders has received little attention by the medical community. To better understand the potential risk of PFAS on human ovarian function, additional experimental studies using PFAS doses equivalent to the exposure levels found in the general human population and mixtures of compounds are required. Prospective investigations in human populations are also warranted to ensure the temporality of PFAS exposure and health endpoints and to minimise the possibility of reverse causality.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Ding N, Harlow SD, Randolph JF, et al. Perfluoroalkyl and polyfluoroalkyl substances (PFAS) and their effects on the ovary. Hum Reprod Update. 2020. PMID: 32476019. doi:10.1093/humupd/dmaa018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。